A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents
We report the results of a pilot study of a BU–fludarabine–alemtuzumab (BFA)-reduced toxicity conditioning (RTC) followed by allogeneic hematopoietic SCT (AlloHSCT) in 12 children and adolescents (
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2011-06, Vol.46 (6), p.790-799 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 799 |
|---|---|
| container_issue | 6 |
| container_start_page | 790 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 46 |
| creator | Styczynski, J Tallamy, B Waxman, I van de Ven, C Milone, M C Shaw, L M Harrison, L Morris, E Satwani, P Bhatia, M George, D Bradley, M B Garvin, J H Schwartz, J Baxter-Lowe, L A Cairo, M S |
| description | We report the results of a pilot study of a BU–fludarabine–alemtuzumab (BFA)-reduced toxicity conditioning (RTC) followed by allogeneic hematopoietic SCT (AlloHSCT) in 12 children and adolescents ( |
| doi_str_mv | 10.1038/bmt.2010.209 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_883048731</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A259379866</galeid><sourcerecordid>A259379866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c543t-ff19db94d4f2633a4b39988f23cf7c2f1aa09536f196de907e8711d23808e1603</originalsourceid><addsrcrecordid>eNp1kk2PFCEQhjtG446rN8-GaNTL9ghNf8BxnPiVbOLB3XOHhmKaDQ0j0NHxj_h3ZTKj45o1JJCinnqrKKoonhK8JJiyN8OUlhXOVoX5vWJB6q4tG9o294sFrlpWUtrys-JRjDcYk7rGzcPirMKMsLomi-LnCm2N9QnFNKsd8hoFULMEhZL_bqRJOyS9UyYZ74zboG8mjejt9QXSdlYiiME4QMIpJCxMaf4xT2JAA2gfAKUxu6z1G3BgJBphEslvvYGUrS_rK2QckqOxKoA7aChvIUpwKT4uHmhhIzw5nufF9ft3V-uP5eXnD5_Wq8tSNjVNpdaEq4HXqtZVS6moB8o5Y7qiUney0kQIzHM3MtYq4LgD1hGiKsowA9Jiel68Puhug_86Q0z9ZHIF1goHfo49YxTXrKMkk8__IW_8HFwurs-amHac0Ay9-B9UtXVF2oZQfKI2uWu9cdqnIOQ-cb-qGp6lWNtmankHlZeCyeRPAW3y_a2AV38FjCBsGqO38_7v4m3w4gDK4GMMoPttMJMIu57gfj9UfR6qfj9UeeMZf3Z81DxMoP7Av6coAy-PgIhSWB2EkyaeuDqn5s1eqDxwMbvcBsKpO3cm_gULdeGW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642165130</pqid></control><display><type>article</type><title>A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Styczynski, J ; Tallamy, B ; Waxman, I ; van de Ven, C ; Milone, M C ; Shaw, L M ; Harrison, L ; Morris, E ; Satwani, P ; Bhatia, M ; George, D ; Bradley, M B ; Garvin, J H ; Schwartz, J ; Baxter-Lowe, L A ; Cairo, M S</creator><creatorcontrib>Styczynski, J ; Tallamy, B ; Waxman, I ; van de Ven, C ; Milone, M C ; Shaw, L M ; Harrison, L ; Morris, E ; Satwani, P ; Bhatia, M ; George, D ; Bradley, M B ; Garvin, J H ; Schwartz, J ; Baxter-Lowe, L A ; Cairo, M S</creatorcontrib><description>We report the results of a pilot study of a BU–fludarabine–alemtuzumab (BFA)-reduced toxicity conditioning (RTC) followed by allogeneic hematopoietic SCT (AlloHSCT) in 12 children and adolescents (<21 years) with malignant and non-malignant diseases. Stem cell sources were: two unrelated cord blood, one unrelated BM, two related and seven unrelated PBSC. Positive CD34 selection was performed in five unrelated PBSC grafts. RCT was carried out with BFA, and GVHD prophylaxis was FK506 and mycophenolate mofetil. The median time for neutrophil and platelet engraftment was 16 and 31 days, respectively. The
P
of developing ⩾grade II, ⩾grade III aGVHD and cGVHD was 41.6, 25 and 9%, respectively. Only 1 out of 12 developed ⩾grade III toxicity. There was one primary and no secondary graft failure. Mixed donor chimerism on day 100 and 1 year was median 99 and 96%, respectively; ⩾90% of recipients achieved ⩾80% donor chimerism. The 3-year overall survival (OS) in all patients was 91.7±8% (100% for malignant vs 80% for non-malignant diseases, ns). In all, 11 (91%) patients remain alive at median 2.8 (0.3–6.8) years. RTC followed by AlloHSCT, based on BFA conditioning, is feasible and tolerable in children and adolescents, and results in prompt achievement of durable mixed donor chimerism and excellent OS.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2010.209</identifier><identifier>PMID: 20818441</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/92/436/1729 ; 692/699/67 ; 692/700/565/545/576/1955 ; Adolescent ; Adolescents ; Alemtuzumab ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Neoplasm ; Antimitotic agents ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Busulfan ; CD34 antigen ; Cell Biology ; Child ; Child, Preschool ; Children ; Chimerism ; Conditioning ; Cord blood ; Drugs ; Female ; Fludarabine ; Graft rejection ; Graft Survival ; Graft vs Host Disease - classification ; Graft-versus-host reaction ; Grafts ; Health aspects ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic Stem Cell Transplantation - mortality ; Hematopoietic stem cells ; Humans ; Internal Medicine ; Leukocytes (neutrophilic) ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Mycophenolate mofetil ; Mycophenolic acid ; original-article ; Pilot Projects ; Prophylaxis ; Public Health ; Stem cell transplantation ; Stem Cells ; Survival Analysis ; Tacrolimus ; Teenagers ; Toxicity ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation Chimera ; Transplantation Conditioning - adverse effects ; Transplantation Conditioning - methods ; Transplantation, Homologous ; Vidarabine - analogs & derivatives ; Young Adult</subject><ispartof>Bone marrow transplantation (Basingstoke), 2011-06, Vol.46 (6), p.790-799</ispartof><rights>Macmillan Publishers Limited 2011</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Nature Publishing Group</rights><rights>Macmillan Publishers Limited 2011.</rights><rights>Copyright Nature Publishing Group Jun 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c543t-ff19db94d4f2633a4b39988f23cf7c2f1aa09536f196de907e8711d23808e1603</citedby><cites>FETCH-LOGICAL-c543t-ff19db94d4f2633a4b39988f23cf7c2f1aa09536f196de907e8711d23808e1603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2010.209$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2010.209$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24259959$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20818441$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Styczynski, J</creatorcontrib><creatorcontrib>Tallamy, B</creatorcontrib><creatorcontrib>Waxman, I</creatorcontrib><creatorcontrib>van de Ven, C</creatorcontrib><creatorcontrib>Milone, M C</creatorcontrib><creatorcontrib>Shaw, L M</creatorcontrib><creatorcontrib>Harrison, L</creatorcontrib><creatorcontrib>Morris, E</creatorcontrib><creatorcontrib>Satwani, P</creatorcontrib><creatorcontrib>Bhatia, M</creatorcontrib><creatorcontrib>George, D</creatorcontrib><creatorcontrib>Bradley, M B</creatorcontrib><creatorcontrib>Garvin, J H</creatorcontrib><creatorcontrib>Schwartz, J</creatorcontrib><creatorcontrib>Baxter-Lowe, L A</creatorcontrib><creatorcontrib>Cairo, M S</creatorcontrib><title>A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>We report the results of a pilot study of a BU–fludarabine–alemtuzumab (BFA)-reduced toxicity conditioning (RTC) followed by allogeneic hematopoietic SCT (AlloHSCT) in 12 children and adolescents (<21 years) with malignant and non-malignant diseases. Stem cell sources were: two unrelated cord blood, one unrelated BM, two related and seven unrelated PBSC. Positive CD34 selection was performed in five unrelated PBSC grafts. RCT was carried out with BFA, and GVHD prophylaxis was FK506 and mycophenolate mofetil. The median time for neutrophil and platelet engraftment was 16 and 31 days, respectively. The
P
of developing ⩾grade II, ⩾grade III aGVHD and cGVHD was 41.6, 25 and 9%, respectively. Only 1 out of 12 developed ⩾grade III toxicity. There was one primary and no secondary graft failure. Mixed donor chimerism on day 100 and 1 year was median 99 and 96%, respectively; ⩾90% of recipients achieved ⩾80% donor chimerism. The 3-year overall survival (OS) in all patients was 91.7±8% (100% for malignant vs 80% for non-malignant diseases, ns). In all, 11 (91%) patients remain alive at median 2.8 (0.3–6.8) years. RTC followed by AlloHSCT, based on BFA conditioning, is feasible and tolerable in children and adolescents, and results in prompt achievement of durable mixed donor chimerism and excellent OS.</description><subject>631/92/436/1729</subject><subject>692/699/67</subject><subject>692/700/565/545/576/1955</subject><subject>Adolescent</subject><subject>Adolescents</subject><subject>Alemtuzumab</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antibodies, Monoclonal</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antibodies, Neoplasm</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Busulfan</subject><subject>CD34 antigen</subject><subject>Cell Biology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Chimerism</subject><subject>Conditioning</subject><subject>Cord blood</subject><subject>Drugs</subject><subject>Female</subject><subject>Fludarabine</subject><subject>Graft rejection</subject><subject>Graft Survival</subject><subject>Graft vs Host Disease - classification</subject><subject>Graft-versus-host reaction</subject><subject>Grafts</subject><subject>Health aspects</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic Stem Cell Transplantation - mortality</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Leukocytes (neutrophilic)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Mycophenolate mofetil</subject><subject>Mycophenolic acid</subject><subject>original-article</subject><subject>Pilot Projects</subject><subject>Prophylaxis</subject><subject>Public Health</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival Analysis</subject><subject>Tacrolimus</subject><subject>Teenagers</subject><subject>Toxicity</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation Chimera</subject><subject>Transplantation Conditioning - adverse effects</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplantation, Homologous</subject><subject>Vidarabine - analogs & derivatives</subject><subject>Young Adult</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kk2PFCEQhjtG446rN8-GaNTL9ghNf8BxnPiVbOLB3XOHhmKaDQ0j0NHxj_h3ZTKj45o1JJCinnqrKKoonhK8JJiyN8OUlhXOVoX5vWJB6q4tG9o294sFrlpWUtrys-JRjDcYk7rGzcPirMKMsLomi-LnCm2N9QnFNKsd8hoFULMEhZL_bqRJOyS9UyYZ74zboG8mjejt9QXSdlYiiME4QMIpJCxMaf4xT2JAA2gfAKUxu6z1G3BgJBphEslvvYGUrS_rK2QckqOxKoA7aChvIUpwKT4uHmhhIzw5nufF9ft3V-uP5eXnD5_Wq8tSNjVNpdaEq4HXqtZVS6moB8o5Y7qiUney0kQIzHM3MtYq4LgD1hGiKsowA9Jiel68Puhug_86Q0z9ZHIF1goHfo49YxTXrKMkk8__IW_8HFwurs-amHac0Ay9-B9UtXVF2oZQfKI2uWu9cdqnIOQ-cb-qGp6lWNtmankHlZeCyeRPAW3y_a2AV38FjCBsGqO38_7v4m3w4gDK4GMMoPttMJMIu57gfj9UfR6qfj9UeeMZf3Z81DxMoP7Av6coAy-PgIhSWB2EkyaeuDqn5s1eqDxwMbvcBsKpO3cm_gULdeGW</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Styczynski, J</creator><creator>Tallamy, B</creator><creator>Waxman, I</creator><creator>van de Ven, C</creator><creator>Milone, M C</creator><creator>Shaw, L M</creator><creator>Harrison, L</creator><creator>Morris, E</creator><creator>Satwani, P</creator><creator>Bhatia, M</creator><creator>George, D</creator><creator>Bradley, M B</creator><creator>Garvin, J H</creator><creator>Schwartz, J</creator><creator>Baxter-Lowe, L A</creator><creator>Cairo, M S</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20110601</creationdate><title>A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents</title><author>Styczynski, J ; Tallamy, B ; Waxman, I ; van de Ven, C ; Milone, M C ; Shaw, L M ; Harrison, L ; Morris, E ; Satwani, P ; Bhatia, M ; George, D ; Bradley, M B ; Garvin, J H ; Schwartz, J ; Baxter-Lowe, L A ; Cairo, M S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c543t-ff19db94d4f2633a4b39988f23cf7c2f1aa09536f196de907e8711d23808e1603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/92/436/1729</topic><topic>692/699/67</topic><topic>692/700/565/545/576/1955</topic><topic>Adolescent</topic><topic>Adolescents</topic><topic>Alemtuzumab</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antibodies, Monoclonal</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antibodies, Neoplasm</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Busulfan</topic><topic>CD34 antigen</topic><topic>Cell Biology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Chimerism</topic><topic>Conditioning</topic><topic>Cord blood</topic><topic>Drugs</topic><topic>Female</topic><topic>Fludarabine</topic><topic>Graft rejection</topic><topic>Graft Survival</topic><topic>Graft vs Host Disease - classification</topic><topic>Graft-versus-host reaction</topic><topic>Grafts</topic><topic>Health aspects</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic Stem Cell Transplantation - mortality</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Leukocytes (neutrophilic)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Mycophenolate mofetil</topic><topic>Mycophenolic acid</topic><topic>original-article</topic><topic>Pilot Projects</topic><topic>Prophylaxis</topic><topic>Public Health</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival Analysis</topic><topic>Tacrolimus</topic><topic>Teenagers</topic><topic>Toxicity</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation Chimera</topic><topic>Transplantation Conditioning - adverse effects</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplantation, Homologous</topic><topic>Vidarabine - analogs & derivatives</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Styczynski, J</creatorcontrib><creatorcontrib>Tallamy, B</creatorcontrib><creatorcontrib>Waxman, I</creatorcontrib><creatorcontrib>van de Ven, C</creatorcontrib><creatorcontrib>Milone, M C</creatorcontrib><creatorcontrib>Shaw, L M</creatorcontrib><creatorcontrib>Harrison, L</creatorcontrib><creatorcontrib>Morris, E</creatorcontrib><creatorcontrib>Satwani, P</creatorcontrib><creatorcontrib>Bhatia, M</creatorcontrib><creatorcontrib>George, D</creatorcontrib><creatorcontrib>Bradley, M B</creatorcontrib><creatorcontrib>Garvin, J H</creatorcontrib><creatorcontrib>Schwartz, J</creatorcontrib><creatorcontrib>Baxter-Lowe, L A</creatorcontrib><creatorcontrib>Cairo, M S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Styczynski, J</au><au>Tallamy, B</au><au>Waxman, I</au><au>van de Ven, C</au><au>Milone, M C</au><au>Shaw, L M</au><au>Harrison, L</au><au>Morris, E</au><au>Satwani, P</au><au>Bhatia, M</au><au>George, D</au><au>Bradley, M B</au><au>Garvin, J H</au><au>Schwartz, J</au><au>Baxter-Lowe, L A</au><au>Cairo, M S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>46</volume><issue>6</issue><spage>790</spage><epage>799</epage><pages>790-799</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>We report the results of a pilot study of a BU–fludarabine–alemtuzumab (BFA)-reduced toxicity conditioning (RTC) followed by allogeneic hematopoietic SCT (AlloHSCT) in 12 children and adolescents (<21 years) with malignant and non-malignant diseases. Stem cell sources were: two unrelated cord blood, one unrelated BM, two related and seven unrelated PBSC. Positive CD34 selection was performed in five unrelated PBSC grafts. RCT was carried out with BFA, and GVHD prophylaxis was FK506 and mycophenolate mofetil. The median time for neutrophil and platelet engraftment was 16 and 31 days, respectively. The
P
of developing ⩾grade II, ⩾grade III aGVHD and cGVHD was 41.6, 25 and 9%, respectively. Only 1 out of 12 developed ⩾grade III toxicity. There was one primary and no secondary graft failure. Mixed donor chimerism on day 100 and 1 year was median 99 and 96%, respectively; ⩾90% of recipients achieved ⩾80% donor chimerism. The 3-year overall survival (OS) in all patients was 91.7±8% (100% for malignant vs 80% for non-malignant diseases, ns). In all, 11 (91%) patients remain alive at median 2.8 (0.3–6.8) years. RTC followed by AlloHSCT, based on BFA conditioning, is feasible and tolerable in children and adolescents, and results in prompt achievement of durable mixed donor chimerism and excellent OS.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>20818441</pmid><doi>10.1038/bmt.2010.209</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2011-06, Vol.46 (6), p.790-799 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_883048731 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 631/92/436/1729 692/699/67 692/700/565/545/576/1955 Adolescent Adolescents Alemtuzumab Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Neoplasm Antimitotic agents Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone marrow, stem cells transplantation. Graft versus host reaction Busulfan CD34 antigen Cell Biology Child Child, Preschool Children Chimerism Conditioning Cord blood Drugs Female Fludarabine Graft rejection Graft Survival Graft vs Host Disease - classification Graft-versus-host reaction Grafts Health aspects Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - mortality Hematopoietic stem cells Humans Internal Medicine Leukocytes (neutrophilic) Male Medical sciences Medicine Medicine & Public Health Monoclonal antibodies Mycophenolate mofetil Mycophenolic acid original-article Pilot Projects Prophylaxis Public Health Stem cell transplantation Stem Cells Survival Analysis Tacrolimus Teenagers Toxicity Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation Chimera Transplantation Conditioning - adverse effects Transplantation Conditioning - methods Transplantation, Homologous Vidarabine - analogs & derivatives Young Adult |
| title | A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T05%3A43%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20pilot%20study%20of%20reduced%20toxicity%20conditioning%20with%20BU,%20fludarabine%20and%20alemtuzumab%20before%20the%20allogeneic%20hematopoietic%20SCT%20in%20children%20and%20adolescents&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Styczynski,%20J&rft.date=2011-06-01&rft.volume=46&rft.issue=6&rft.spage=790&rft.epage=799&rft.pages=790-799&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/bmt.2010.209&rft_dat=%3Cgale_proqu%3EA259379866%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642165130&rft_id=info:pmid/20818441&rft_galeid=A259379866&rfr_iscdi=true |